Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/17661202http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/17661202http://www.w3.org/2000/01/rdf-schema#comment"

Purpose

There is no consensus regarding the optimal tumor markers for melanoma. We compared 3 tumor markers, TA90-immune complex (TA90IC), melanoma-inhibiting activity (MIA) protein, and S100B protein in Stage III melanoma patients undergoing adjuvant vaccine immunotherapy.

Experimental design

The serum of 75 patients representing 3 prognostic cohorts was assayed for the tumor markers prior to initiating immunotherapy and at 6 follow-up time points. Upper limits of normal for TA90IC, MIA and S100B were set at OD 0.41, 8.5 ng/ml, and 2.5 microg/l, respectively.

Results

At least 1 marker became elevated prior to 41 (80 percent) of 51 recurrences. TA90IC was the earliest elevated marker in 29 (57 percent), MIA in 11 (22 percent), and S100B in 4 (8 percent). Multivariate regression analysis revealed that TA90IC was an independent predictor of survival when elevation occurred between 2 weeks and 3 months, whereas MIA was an independent predictor at 4-6 months. In the poor prognostic cohort, mean values for MIA and S100B increased progressively, whereas TA90IC exhibited a parabolic curve.

Conclusion

In this patient population, TA90IC and MIA were complementary; elevation of the immune complex preceded elevation of the tumor antigen in patients who developed recurrence. Additional studies in populations not receiving vaccine will further clarify the clinical utility of these assays."xsd:string
http://purl.uniprot.org/citations/17661202http://purl.org/dc/terms/identifier"doi:10.1080/07357900701208634"xsd:string
http://purl.uniprot.org/citations/17661202http://purl.uniprot.org/core/author"Lee C."xsd:string
http://purl.uniprot.org/citations/17661202http://purl.uniprot.org/core/author"Ye X."xsd:string
http://purl.uniprot.org/citations/17661202http://purl.uniprot.org/core/author"Gupta R.K."xsd:string
http://purl.uniprot.org/citations/17661202http://purl.uniprot.org/core/author"Essner R."xsd:string
http://purl.uniprot.org/citations/17661202http://purl.uniprot.org/core/author"Yee R."xsd:string
http://purl.uniprot.org/citations/17661202http://purl.uniprot.org/core/author"Elashoff D."xsd:string
http://purl.uniprot.org/citations/17661202http://purl.uniprot.org/core/author"Morton D.L."xsd:string
http://purl.uniprot.org/citations/17661202http://purl.uniprot.org/core/author"Faries M.B."xsd:string
http://purl.uniprot.org/citations/17661202http://purl.uniprot.org/core/author"Foshag L.J."xsd:string
http://purl.uniprot.org/citations/17661202http://purl.uniprot.org/core/author"Leopoldo Z."xsd:string
http://purl.uniprot.org/citations/17661202http://purl.uniprot.org/core/date"2007"xsd:gYear
http://purl.uniprot.org/citations/17661202http://purl.uniprot.org/core/name"Cancer Invest"xsd:string
http://purl.uniprot.org/citations/17661202http://purl.uniprot.org/core/pages"285-293"xsd:string
http://purl.uniprot.org/citations/17661202http://purl.uniprot.org/core/title"A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients."xsd:string
http://purl.uniprot.org/citations/17661202http://purl.uniprot.org/core/volume"25"xsd:string
http://purl.uniprot.org/citations/17661202http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/17661202
http://purl.uniprot.org/citations/17661202http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/17661202
http://purl.uniprot.org/uniprot/#_A0A0S2Z4C5-mappedCitation-17661202http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/17661202
http://purl.uniprot.org/uniprot/#_A8MRB1-mappedCitation-17661202http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/17661202
http://purl.uniprot.org/uniprot/#_P04271-mappedCitation-17661202http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/17661202
http://purl.uniprot.org/uniprot/#_Q16674-mappedCitation-17661202http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/17661202
http://purl.uniprot.org/uniprot/A8MRB1http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/17661202
▶